TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05303519

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: safusidenib
Description: safusidenib administered continuously as dosed single agent orally on Days 1 to 28 of a 28-day cycle. Subjects may continue treatment with agent safusidenib until disease progression or development of other unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: safusidenib
Description: safusidenib administered continuously as dosed single agent orally on Days 1 to 28 of a 28-day cycle. Subjects may continue treatment with agent safusidenib until disease progression or development of other unacceptable toxicity.
Study: NCT04925271

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: X-Tack
Description: The mucosal or submucosal defect is closed with X-Tack.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Overstitch
Description: The mucosal or submucosal defect is closed with Overstitch.
Study: NCT05158660

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial duplex sonography
Description: it is an imaging device that will measure the intracerebral hematoma expansion
Study: NCT05187325

Intervention type: OTHER
Intervention: no intervention
Description: there is no intervention

Intervention type: OTHER
Intervention: no intervention
Description: there is no intervention
Study: NCT04547179

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fremanezumab-Vfrm
Description: Patients will receive three injections of Ajovy® if in the corresponding arm of the study.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BLAfit®
Description: Usage of the BLAfit device, a fixed orthotic appliance that allows users to tone facial muscles with one minute usage per day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Patients will receive three injections of saline if in the corresponding arm of the study. This is a placebo meant to simulate the Ajovy® injection.
Study: NCT06678568

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: telemedicine follow-up in 3rd week
Description: Intervention group will be appointed with telemedicine follow-up in 3rd week after injury, instead of hospital follow-up visit.
Study: NCT06685770

Intervention type: OTHER
Intervention: Mini mental state assessment test
Description: Breast cancer is a very common and important disease in the female population around the world. Anesthesia management during surgery for this disease in the postoperative period should be carefully planned. It will be important to examine the neurocognitive effects of anesthesia management in the postoperative period in this patient group. Today, inhaler and total intravenous anesthesia have advantages as well as disadvantages. It would be valuable to examine its neurocognitive effects in this patient group. In this study, the frequently used Mini mental state assessment test and Mini-cog test will be used.With mini mental state assessment, the patient is asked a number of simple questions to evaluate cognitive functions and each question has certain points. Changes in these score levels preoperatively and postoperatively will be compared within each patient. At the end of the study, preoperative and postoperative changes will be compared statistically between the groups.
Study: NCT05314062

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: FeSO4
Description: 2 FeSO4 supplements containing 27 mg elemental iron/supplements (54 mg total iron)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ao iron
Description: 2 Ao iron supplements containing 27 mg elemental iron/supplements (54 mg total iron)
Study: NCT06174064

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Broadband Light treatment
Description: While shielding the eyes, multiple passes of broadband light will be applied to the upper cheeks and eyelids after applying topical lidocaine.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Broadband Light treatment
Description: While shielding the eyes, multiple passes of broadband light will be applied to the upper cheeks and eyelids after applying topical lidocaine.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham broadband light treatment
Description: The light will be occluded on the usual BBL device so that no treatment is delivered but the preparation and procedure will otherwise be the same.
Study: NCT05910177

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Karelizumab combined with etoposide and cisplatin
Description: Karelizumab：200 mg，ivgtt，D1，q3w； Cisplatin：75 mg/m2，ivgtt，D1，q3w； Etoposide：100 mg/m2，ivgtt，D1\~3，q3w
Study: NCT05417243

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trauma life support training
Description: Clusters are randomised for their residents to be trained in one of two trauma life support training programs or to continue providing standard care.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trauma life support training
Description: Clusters are randomised for their residents to be trained in one of two trauma life support training programs or to continue providing standard care.
Study: NCT06468722

Intervention type: BEHAVIORAL
Intervention: Exercise-based rehabilitation
Description: Patients performed regular physical exercise during inpatient rehabilitation
Study: NCT04933240

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamoxifen Citrate 10Mg Tab
Description: nonsteroidal antiestrogen for oral administration in 10 mg tablets. Each tablet contains 15.2 mg of tamoxifen citrate which is equivalent to 10 mg of tamoxifen.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estradiol
Description: estradiol tablets for oral administration contains 1 mg of micronized estradiol per tablet.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A sugar tablet that does not contain any active medicine
Study: NCT05568173

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Boxing Training
Description: In addition to boxing training, stretching exercises and posture training will be given at BG. A physiotherapist with a boxing training certificate will perform modified boxing training that progresses according to the degree of difficulty. There will be four difficulty levels. The complexity of the exercises will increase at 2-week intervals as the patient progresses. As a result, 0-2 weeks 1st level, 2-4 weeks 2nd level, 4-6 weeks 3rd level and 6-8 weeks 4th level exercises will be done.~In the first level, patients will be asked to punch the fixed boxing mat hanging on the wall with various instructions. Then, in levels 2-4, target gloves and heavy punching bags will be used to increase the difficulty level. As the sessions progress, the resistance and frequencies between the levels will be increased by the physiotherapist. There will be 3 sessions of 30-minute boxing training per week for 8 weeks at BG.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Scapular Stabilization
Description: In addition to scapular stabilization training, stretching exercises and posture training will be given in SSG. Progressive strengthening training for the scapular muscles will be used in the SSG. There will be four difficulty levels. The complexity of the exercises will increase at 2-week intervals as the patient progresses. As a result, 0-2 weeks 1st level, 2-4 weeks 2nd level, 4-6 weeks 3rd level and 6-8 weeks 4th level exercises will be done.~At the first level, scapular clock exercise, obstacle crossing exercise, wall gliding exercise with teraband, push up exercise, trunk rotation and maximum hip flexion will be performed. Then at levels 2-4, as the levels increase, the exercises at the first level will be more difficult (ball weight, surface, number of hurdles and hurdle crossing exercise position, by changing the teraband elasticity, push-up position). In SSG, 3 sessions of 30-minute scapular stabilization training will be applied per week for 8 weeks.
Study: NCT04754243

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gonadotropin
Description: Giving patients gonadotropins and antagonist cetrotide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard protocol in IUI
Description: Giving patients gonadotropins without antagonist cetrotide
Study: NCT06391346

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MSOT
Description: Non-invasive transcutaneous imaging of muscle components via infrared and near-infrared laser pulses
Study: NCT06393543

Intervention type: OTHER
Intervention: No intervention, only registration
Description: No intervention, only registration

Intervention type: OTHER
Intervention: No intervention, only registration
Description: No intervention, only registration
Study: NCT06313827

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise plus Monitoring Group (TG-2)
Description: Participants will receive their usual physiotherapy treatment and user education on bronchial care and hygiene, plus a dossier on the use of monitoring equipment such as: pulse oximeter, thermometer, digital spirometer, Medical Research Council dyspnoea scale. If the patient detects an exacerbation (due to symptoms or monitoring of the equipment), they can contact a physiotherapist who can adjust the treatment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise plus monitoring and follow-up group (TGF-3)
Description: Participants who will receive their usual physiotherapy treatment and user education on bronchial care and hygiene, plus dossiers on the use of monitoring equipment ; plus telematic control of exacerbations (questionnaires and monitoring of the parameters of the aforementioned equipment). Depending on the follow-up, physiotherapy treatment will be adjusted.~The questionnaire includes tracking of the following parameters: cough, secretions (quantity, colour, viscosity), chest tightness, dyspnoea, exercise tolerance, tiredness and appetite).~The follow-up will consist of weekly filling the spreadsheet to which the physiotherapist will have access and who, by reviewing the parameters, will be able to adjust the treatment. The physiotherapist will systematically make videocalls to the participants and if the follow-up values require it, he/she will call every week.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Group (CG-1)
Description: Participants who will receive their usual physiotherapy treatment and user education on bronchial care and hygiene
Study: NCT05805930

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anakinra
Description: : Patients will continue daily treatment with anakinra up to week 12. Treatment will be then progressively tapered through the reduction of an administration of the drug per week. Reductions will be performed every 2 weeks up to discontinuation. Therefore, if a relapse does not occur, the treatment will be withdrawn at week 24.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Steroids will be progressively tapered with a reduction of 0,1-0,15 mg/kg/day of prednisone (or 5 mg in patients in treatment with the maximum dosage of 50 mg/day) from the ongoing treatment every week up to discontinuation. If a relapse does not occur, the treatment will be withdrawn in a period of time of 10 weeks.
Study: NCT05936125

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Annuloplasty Using Flexible Band
Description: Tricuspid valve annuloplasty using a flexible band; (Polyethylene terephthalate band): (Dacron band)
Study: NCT06284096

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducation
Description: The study is planned to consist of 7 sessions, occurring once a week, with approximately 70-80 minutes allocated for each session. Considering the attention span of the participants, the sessions will be divided into two parts, with a session lasting 30-40 minutes followed by a 15-minute break.
Study: NCT04542304

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metolazone
Description: Participants will be given a metolazone for the 1-week study period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will be given a placebo for the 1-week study period.
Study: NCT06685770

Intervention type: OTHER
Intervention: Mini mental state assessment test
Description: Breast cancer is a very common and important disease in the female population around the world. Anesthesia management during surgery for this disease in the postoperative period should be carefully planned. It will be important to examine the neurocognitive effects of anesthesia management in the postoperative period in this patient group. Today, inhaler and total intravenous anesthesia have advantages as well as disadvantages. It would be valuable to examine its neurocognitive effects in this patient group. In this study, the frequently used Mini mental state assessment test and Mini-cog test will be used.With mini mental state assessment, the patient is asked a number of simple questions to evaluate cognitive functions and each question has certain points. Changes in these score levels preoperatively and postoperatively will be compared within each patient. At the end of the study, preoperative and postoperative changes will be compared statistically between the groups.

Intervention type: OTHER
Intervention: Mini-cog test
Description: Breast cancer is a very common and important disease in the female population around the world. Anesthesia management during surgery for this disease in the postoperative period should be carefully planned. It will be important to examine the neurocognitive effects of anesthesia management in the postoperative period in this patient group. Today, inhaler and total intravenous anesthesia have advantages as well as disadvantages. It would be valuable to examine its neurocognitive effects in this patient group. In this study, the frequently used Mini-cog test will be used.With Mini-cog test, the patient is asked a number of simple questions to evaluate cognitive functions and each question has certain points. Changes in these score levels preoperatively and postoperatively will be compared within each patient. At the end of the study, preoperative and postoperative changes will be compared statistically between the groups.

Intervention type: OTHER
Intervention: Mini-cog test
Description: Breast cancer is a very common and important disease in the female population around the world. Anesthesia management during surgery for this disease in the postoperative period should be carefully planned. It will be important to examine the neurocognitive effects of anesthesia management in the postoperative period in this patient group. Today, inhaler and total intravenous anesthesia have advantages as well as disadvantages. It would be valuable to examine its neurocognitive effects in this patient group. In this study, the frequently used Mini-cog test will be used.With Mini-cog test, the patient is asked a number of simple questions to evaluate cognitive functions and each question has certain points. Changes in these score levels preoperatively and postoperatively will be compared within each patient. At the end of the study, preoperative and postoperative changes will be compared statistically between the groups.
Study: NCT06690840

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab in combination with Cyclophosphamide and Vinorelbine
Description: Patients will receive Atezolizumab in combination with Cyclophosphamide and Vinorelbine in 28-day cycles
Study: NCT06691360

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK137
Description: IV infusion, specified dose on specified days.
Study: NCT06690255

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pivotal Response Treatment
Description: PRT will target functional communication abilities
Study: NCT06691178

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Optical coherence tomography (OCT)
Description: The OCT device with cover will be used to take measurements at four areas in the vaginal canal: the proximal posterior aspect, proximal anterior, distal anterior, and distal posterior. The proximal and distal points will be marked on the OCT cover during the first set of measurements. Markings will be used to guide measurements during subsequent visits.

Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: Optical coherence tomography (OCT)
Description: The OCT device with cover will be used to take measurements at four areas in the vaginal canal: the proximal posterior aspect, proximal anterior, distal anterior, and distal posterior. The proximal and distal points will be marked on the OCT cover during the first set of measurements. Markings will be used to guide measurements during subsequent visits.
Study: NCT05857943

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AEYE-DS Software
Description: Eligible participants will undergo the following procedures: Photographic imaging of each eye using a funduscopy camera device. Images obtained will be sent to the AEYE-DS software for analysis. -Additional photographic and OCT images will be obtained using a second funduscopy/OCT camera device. Images obtained will be sent to a professional reading center for analysis. -All study subjects will have their pupils dilated using dilation drops.
Study: NCT05743036

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZN-c3
Description: ZN-c3 tablet by mouth, in combination with encorafenib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZN-c3
Description: ZN-c3 tablet by mouth, in combination with encorafenib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Encorafenib
Description: Encorafenib capsule by mouth, in combination with ZN-c3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Encorafenib
Description: Encorafenib capsule by mouth, in combination with ZN-c3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Infusion
Study: NCT04099342

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FEAST
Description: FEAST with standard electrode configuration and current flow

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FEAST
Description: FEAST with standard electrode configuration and current flow
Study: NCT06253325

Intervention type: DIAGNOSTIC_TEST
Intervention: Measuring tissue oxygenation
Description: Measuring oxygen content of arteries, capillaries and veins

Intervention type: DIAGNOSTIC_TEST
Intervention: Procalcitonin
Description: Blood test

Intervention type: DIAGNOSTIC_TEST
Intervention: Mid-regional proadrenomedullin
Description: Blood test looking at inflammation in the body

Intervention type: DIAGNOSTIC_TEST
Intervention: Hand-held video microscope
Description: A handheld video microscope that looks at blood flow through the capillaries of the tongue
Study: NCT04642053

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dynamic Temporal and Tactile Cuing
Description: Dynamic Temporal and Tactile Cuing is based on principles of integral stimulation where the client watches, listens to and imitates the clinician (Strand, 2020). Treatment will begin by training the child to imitate and simultaneously produce syllables/words with the clinician. Sessions will focus on establishing accurate movement transitions in treated words. The child will be asked to imitate the clinician's production of the target. If the child's imitation is inaccurate, they will be instructed to simultaneously produce the target with the clinician. Simultaneous productions will continue to provide practice opportunity with maximal cuing. As the child gains greater accuracy, simultaneous productions will be faded and direct imitation will be attempted again. Over the course of treatment, the movement gesture will be shaped with the goal being accurate production with normal rate and naturalness.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dynamic Temporal and Tactile Cuing
Description: Dynamic Temporal and Tactile Cuing is based on principles of integral stimulation where the client watches, listens to and imitates the clinician (Strand, 2020). Treatment will begin by training the child to imitate and simultaneously produce syllables/words with the clinician. Sessions will focus on establishing accurate movement transitions in treated words. The child will be asked to imitate the clinician's production of the target. If the child's imitation is inaccurate, they will be instructed to simultaneously produce the target with the clinician. Simultaneous productions will continue to provide practice opportunity with maximal cuing. As the child gains greater accuracy, simultaneous productions will be faded and direct imitation will be attempted again. Over the course of treatment, the movement gesture will be shaped with the goal being accurate production with normal rate and naturalness.
Study: NCT04676802

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NSAID capsules
Description: 1, Ibuprofen 400-mg and 1, Acetaminophen 500-mg capsule per dosage

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Opioid capsule
Description: 1, Oxycodone 5-mg capsule and 1, placebo capsule per dosage
Study: NCT06174896

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Group 1
Description: The LMA Proseal will be inserted directly by hand, without the use of any laryngoscope, as recommended in the instruction manual. The cuff will be gently guided along the hard palate where it is pushed into the hypopharynx and increased resistance is felt, and the cuff will be placed towards the hypopharynx.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Group 2
Description: Appropriately sized laryngoscope blade will be used and after the location of the epiglottis is determined, the tongue and epiglottis will be lifted forward. Then, LMA Proseal will be placed at the point where resistance is felt at a level where the proximal edge of the mask can be seen.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Group 3
Description: After the video laryngoscope is placed with an appropriately sized blade, the location of the epiglottis and vocal cords will be determined and the LMA Proseal will be placed at the point where slight resistance is encountered after the epiglottis is lifted. proximal aspect of LMA
Study: NCT06524583

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 60 mg/m² intravenous (IV) at Day 1 every 3 weeks (4 cycles)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trabectedin
Description: 1.1 mg/m² intravenous (IV) at Day 1 every 3 weeks (4 cycles)
Study: NCT05705167

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plitidepsin
Description: IV infusion over 60-minutes